Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB. Patient s first names. Date of birth.
|
|
|
- Hester Wilcox
- 6 years ago
- Views:
Transcription
1 Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM BEVACIZUMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements (e.g. other language/other communication method) Chemotherapy for Breast cancer Intravenous Bevacizumab Responsible health professional Job title Name of proposed procedure or course of treatment (include brief explanation if medical term not clear) Intravenous Bevacizumab given every two weeks. Treatment continued at the discretion of the treating doctor A separate consent form exists and must be completed for concomitant chemotherapy (Paclitaxel) Location of administration: outpatient day unit inpatient other:.. Statement of health professional (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in consent policy) I have explained the procedure to the patient. In particular, I have explained: The intended benefits
2 Patient identifier/label: Page 2 of 5 Improved survival Control of symptoms Disease control / palliative the aim is not to cure but to control or shrink the disease. The aim is to improve both quality of life and survival Significant, unavoidable or frequently occurring risks: Early side-effects include infusion-related side effects, which are usually mild but rarely can be more severe. These include flu-like symptoms such as a headache, high temperature and chills, skin rash, oversensitivity/ allergic reactions, feeling sick or being sick. You will notice these while the drug is given or sometimes a few hours after treatment. They are usually most noticeable with the first or second infusion, so these infusions may be given more slowly. Common side-effects, which may occur a few days or weeks after treatment include high blood pressure, presence of protein in the urine, fatigue, diarrhoea, nose bleeds, rhinitis, taste changes and dry skin. In combination with chemotherapy, it increases the risk of infection. Contact your doctor or the hospital straight away if: your temperature goes above 38ºC (100.4ºF) you suddenly feel unwell (even with a normal temperature) Rare but potentially serious side-effect is gastro-intestinal perforation and fistula. Contact your doctor if you experience sudden intense abdominal pain. Very rare (less than 0.1%) cases of reversible leukoencephalopathy with seizures, headache, altered mental status and visual disturbances have been described. There is also a rare but serious risk of developing jaw problems (osteonecrosis) most commonly in patients who have previously received or are receiving IV bisphosphonates; a dental examination and appropriate preventive dentistry should be considered prior to starting treatment with bevacizumab. Cancer can increase your risk of developing a blot clot (thrombosis), and having bevacizumab treatment can increase this risk further. A blood clot may cause pain, redness and swelling in a leg, or breathlessness and chest pain. Bevacizumab can also increase your risk of bleeding, and slows wound healing you must tell your doctor straight away if you have any of these symptoms. Bevacizumab may damage the cellular or genetic development of a foetus, leading to the many risks associated with an abnormal pregnancy. Therefore, I have discussed the issues of protected sex. This is an issue for both men and women. Any other risks:...
3 Patient identifier/label: Page 3 of 5 I have discussed what the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, follow-up appointments etc) and location. I have discussed what the procedure is likely to involve, the benefits and risks of any available alternative treatments (including no treatment) and any particular concerns of this patient. The following leaflet/tape has been provided: Macmillan leaflet for bevacizumab 24 hour chemotherapy service contact details.. Signed:. Name (PRINT). Date.... Job title... Contact details (if patient wishes to discuss options later)... Statement of interpreter (where appropriate) Language Line ref: I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand. Signed.. Date... Name (PRINT).. Copy accepted by patient: yes/no (please ring)
4 Patient identifier/label: Page 4 of 5 Statement of patient Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of page 2 which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask we are here to help you. You have the right to change your mind at any time, including after you have signed this form. I agree to the procedure and course of treatment described on this form. I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience. I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health. I have been told about additional procedures which may become necessary during my treatment. I have listed below any procedures which I do not wish to be carried out without further discussion. Patient s signature.. Date.. Name (PRINT) A witness should sign below if the patient is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign here (see notes). Signature Date... Name (PRINT). Confirmation of consent (to be completed by a health professional when the patient is admitted for the procedure, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and wishes the procedure to go ahead. Signed:. Name (PRINT). Date.... Job title... Important notes: (tick if applicable) See also advance decision (eg Jehovah s Witness form) Patient has withdrawn consent (ask patient to sign /date here)....
5 Patient identifier/label: Page 5 of 5 Guidance to health professionals (to be read in conjunction with consent policy) What a consent form is for This form documents the patient s agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoire to health professionals and patients, by providing a check-list of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way, however, should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient. The law on consent See the Department of Health s Reference guide to consent for examination or treatment for a comprehensive summary of the law on consent (also available at Who can give consent Everyone aged 16 or more is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has sufficient understanding and intelligence to enable him or her to understand fully what is proposed, then he or she will have the capacity to give consent for himself or herself. Young people aged 16 and 17, and legally competent younger children, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, some-one with parental responsibility may do so on their behalf and a separate form is available for this purpose. Even where a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child s care, unless the child specifically asks you not to do so. If a patient has the mental capacity to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that the patient has given consent orally or non-verbally. When NOT to use this form If the patient is 18 or over and lacks the capacity to give consent, you should use form 4 (form for adults who lack the capacity to consent to investigation or treatment) instead of this form. A patient lacks capacity if they have an impairment of the mind or brain or disturbance affecting the way their mind or brain works and they cannot: understand information about the decision to be made retain that information in their mind use or weigh that information as part of the decision-making process, or communicate their decision (by talking, using sign language or any other means). You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to so under a Lasting Power of Attorney or as a court appointed deputy. Information Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about significant risks which would affect the judgement of a reasonable patient. Significant has not been legally defined, but the GMC requires doctors to tell patients about serious or frequently occurring risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on page 2 of the form or in the patient s notes. References: 1- South East London Cancer Network, Agreed lists of Chemotherapy Regimens (CDF) 2- Macmillan Cancer Support, Cancer Information 3- Royal Marsden NHS Foundation Trust, Consent Forms
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID Patient s surname/family name Patient s first names Date of birth NHS number (or other identifier)
Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL
Patient identifier/label: Page 1 of 7 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM EC-T: EPIRUBICIN / CYCLOPHOSPHAMIDE - DOCETAXEL Patient s surname/family name Patient s first names Date of birth
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB. Patient s first names.
Patient identifier/label: Page 1 of 5 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CABOZANTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CISPLATIN + ETOPOSIDE ORAL/INTRAVENOUS Patient s surname/family name Patient s first names Date of birth Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE (HIGH DOSE)
Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Bevacizumab + Chemotherapy PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB. Patient s first names.
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 +/- RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ABVD. Patient s first names.
Patient identifier/label: Page 1 of 6 Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS number
PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FERRERI / IELSG PROTOCOL. Patient s first names. Date of birth
Page 1 of 6 FORM FERRERI / IELSG PROTOCOL Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital NHS
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: FEC-P PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Everolimus PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-EC PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine- Carboplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Irinotecan- Capecitabine (CAPIRI) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Nintedanib-Docetaxel PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pembrolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Sunitinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Carboplatin-Etoposide PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Axitinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cisplatin- Capecitabine- Trastuzumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pazopanib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Niraparib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: BEP (5 day) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Zoledronic acid PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Dabrafenib-Trametinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Oxaliplatin- Fluorouracil (FOLFOX) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-Oxaliplatin- Fluorouracil (FLOT) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Ponatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
Patient's surname/family name. Patient's first names. Date of birth. Responsible health professional. Job title. NHS number (or other identifier)
Page 1 of7 Patient's surname/family name Department of Health THE ROYAL MARSDEN NHS FOUNDATION TRUST Robotic-assisted Laparoscopic Prostatectomy (RALP) Patient Agreement to Investigation or Treatment Patient's
Patient agreement to investigation or treatment. Emergency Spinal Discectomy/Decompression. Patient details (or pre-printed label)
CONSENT FORM 1 (VI) Patient agreement to investigation or treatment Emergency Spinal Discectomy/Decompression Patient details (or pre-printed label) Patient s surname/family name..... Patient s first names..
Patient agreement to investigation or treatment. Spinal Injections. Patient details (or pre-printed label) Patient s surname/family name...
CONSENT FORM 1(VII) Patient agreement to investigation or treatment Spinal Injections Patient details (or pre-printed label) Patient s surname/family name..... Patient s first names.. Date of birth. Responsible
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Laparoscopic radical nephrectomy
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a laparoscopic radical nephrectomy? This is a procedure which involves removal
Canalplasty / excision of exostoses
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a canalplasty? A canalplasty is an operation to remove exostoses, which are
Mastoidectomy or combined approach tympanoplasty
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a cholesteatoma? This is a cyst of skin cells behind your eardrum. As it gets
Percutaneous nephrolithotomy (PCNL)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What does this procedure involve? The breakdown and removal of kidney stones using
West Suffolk Hospital
For staff use only: Patient Details: First names: Hospital no: (Use hospital identification label) West Suffolk Hospital Patient information leaflet Carpal Tunnel Syndrome 2-3 Patient agreement to investigation
Diagnostic and therapeutic pleural aspiration
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Diagnostic and therapeutic pleural aspiration affix patient label Who is this leaflet for? This leaflet
Fitting of an Intrauterine Device (IUD)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an IUD? An IUD is a small T-shaped plastic and copper device that is put into
Percutaneous coronary intervention (angioplasty) +/- rotablation
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label Why do I need this procedure? If you are coming into hospital for a cardiac procedure
Fractured neck of femur
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a fractured neck of femur? A healthy hip joint is vital to normal walking
Direct Current Cardioversion (DCCV)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a This is a procedure carried out under a brief anaesthetic, which uses a
Arthroscopic subacromial decompression (ASD) with or without AC joint removal
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an ASD? Arthroscopic: Using a camera and specially designed instruments we
Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients
Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients This booklet has been written to give you more information about bevacizumab (commonly known as Avastin). This
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Transperineal ultrasound-guided biopsy of the prostate gland
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient biopsy of the prostate gland affix patient label What is a transperineal (TP) ultrasound-guided prostate
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 2) PARENTAL AGREEMENT TO INVESTIGATION OR TREATMENT FOR A CHILD OR YOUNG PERSON Patient Details or pre-printed label Patient
Eloxatin Oxaliplatin concentrated solution for injection
Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common
Total knee replacement
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a total knee replacement? In a total knee replacement the cartilage surfaces
Therapeutic mammoplasty with or without localisation
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is a (localised) therapeutic mammoplasty? A therapeutic mammoplasty is a type
Implantation of a Cardiac Resynchronisation Therapy-Defibrillator (CRT-D)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Implantation of a Cardiac Resynchronisation Therapy-Defibrillator (CRT-D) affix patient label What is
Lipomodelling / Fat grafting
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is lipomodelling? Lipomodelling (or fat grafting) is a procedure used to improve
Implantation of an Implantable Cardioverter Defibrillator (ICD)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an Implantable? Your doctor has recommended that you have an Implantable.
Planning for a time when you cannot make decisions for yourself
Planning for a time when you cannot make decisions for yourself An information leaflet for members of the public Version: October 2013 Introduction The Mental Capacity Act 2005 allows you to plan ahead
Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005
Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005 April 2015 Deciding whether a person has the capacity to make a decision the Mental Capacity Act 2005 The RMBI,
1231 Zoledronic acid in early breast cancer Page 1 of 5
Zoledronic acid in early breast cancer Zoledronic acid in early breast cancer Zoledronic acid is a bisphosphonate. This is treatment which works by slowing down the rate of bone change. In the bone there
Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card)
Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card) Exceptional healthcare, personally delivered What is Cyclophosphamide Cyclophosphamide is a potent
Delayed implant based breast reconstruction
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Delayed implant based breast reconstruction affix patient label What is a delayed implant breast reconstruction?
Patient agreement to investigation or treatment. Anterior Cervical Discectomy & Fusion (ACDF) Patient details (or pre-printed label)
CONSENT FORM 1(V) Patient agreement to investigation or treatment Anterior Cervical Discectomy & Fusion (ACDF) Patient details (or pre-printed label) Patient s surname/family name...... Patient s first
Immediate breast reconstruction using an implant and lower pole (dermal) sling
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Immediate breast reconstruction using an implant and lower pole (dermal) sling affix patient label What
Assessment of Mental Capacity and Best Interest Decisions
Standard Operating Procedure 1 (SOP 1) Assessment of Mental Capacity and Best Interest Decisions Why we have a procedure? This Standard Operating Procedure (SOP) is required to set out how a person s capacity
Tamoxifen Tamoxifen. Your treatment Your doctor or nurse clinician has prescribed for you a treatment which includes the hormonal therapy tamoxifen.
Tamoxifen Tamoxifen This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people hormonal therapy may reduce the risk of cancer coming back, for others
Traztuzumab (Herceptin)
Traztuzumab (Herceptin) Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy alert card. It is important that you know what to do if
Arthroscopic shoulder stabilisation
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient Including repair of the labrum, tightening of the capsule (plication) or SLAP repair affix patient label
Intravenous anti-cancer treatment
Intravenous anti-cancer treatment Information for patients Chemotherapy Name Hospital No Your consultant is Anti-cancer treatment is the term used to describe medicines used to treat cancer including chemotherapy.
Patient agreement to investigation or treatment. Lumbar Spinal Fusion. Patient s surname/family name... Patient s first names.. Date of birth.
CONSENT FORM 1(IV) Patient agreement to investigation or treatment Lumbar Spinal Fusion Patient details (or pre-printed label) Patient s surname/family name..... Patient s first names.. Date of birth.
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Brentuximab vedotin. Brentuximab vedotin
Brentuximab vedotin Brentuximab vedotin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer
Obinutuzumab (lymphoma) Obinutuzumab (lymphoma)
Obinutuzumab (lymphoma) Obinutuzumab (lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of this treatment vary: for some people, this immune therapy may reduce
Bendamustine. Bendamustine. Your treatment Your doctor or nurse clinician has prescribed a course of treatment with bendamustine.
Bendamustine Bendamustine This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back,
CONSENT FORM UROLOGICAL SURGERY
CONSENT FORM for UROLOGICAL SURGERY (Designed in compliance with consent form 1) PATIENT AGREEMENT TO INVESTIGATION OR TREATMENT Patient Details or pre-printed label Patient s NHS Number or Hospital number
Weekly standard dose. Paclitaxel (Taxol) and carboplatin
paclitaxel (taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may
Paclitaxel (Taxol) and carboplatin
Paclitaxel (Taxol) and carboplatin Paclitaxel (Taxol) and carboplatin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may
Consumer Medicine Information March 2009
March 2009 50 (oxaliplatin 50mg power for injection vial) 100 (oxaliplatin 100mg power for injection vial) What is in this leaflet? This leaflet answers some common questions about Powder for injection.
Gemcitabine and Cisplatin (urology)
Gemcitabine and Cisplatin Gemcitabine and Cisplatin (urology) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce
Pentostatin (Nipent )
Pentostatin (Nipent ) Pentostatin (Nipent ) This leaflet is offered as a guide to you and your family. Your treatment will be fully explained by your doctor or nurse, who will be happy to answer any questions.
Oral Etoposide (Lymphoma)
Oral Etoposide (Lymphoma) Oral Etoposide (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk
Leflunomide Treatment Rheumatology Patient Information Leaflet
Leflunomide Treatment Rheumatology Patient Information Leaflet Originator: Dr K Douglas Date: September 2011 Version: 2 Date for Review: September 2014 DGOH Ref No: DGOH/PIL/00217 Contact numbers If your
Abemaciclib (Verzenios ) Abemaciclib (Verzenios )
Abemaciclib (Verzenios ) Abemaciclib (Verzenios ) Abemaciclib is a targeted (biological) therapy. This group of drugs block the growth and spread of cancer. They target and interfere with processes in
Oral anti-cancer treatment
Oral anti-cancer treatment Information for patients Chemotherapy Name Hospital No Your consultant is Anti-cancer treatment is the term used to describe medicines used to treat cancer, including chemotherapy.
Having a Bronchoscopy
Having a Bronchoscopy Department of Respiratory Medicine 2 Patient Information This leaflet will help you and your family to understand more about bronchoscopy. Please read it and ask any questions you
Before you are given CYRAMZA. When you must not be given it
Ramucirumab (rmc) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available information. It does not take the place of
RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)
Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet
Mental capacity and mental illness
Mental capacity and mental illness The Mental Capacity Act 2005 (MCA) Mental capacity is the ability to make your own decisions. If you lose mental capacity the Mental Capacity Act 2005 (MCA) protects
Rituximab treatment in autoimmune blistering diseases
Rituximab treatment in autoimmune blistering diseases This leaflet explains more about having treatment with the medicine rituximab for an autoimmune blistering disease. It includes information about the
Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer)
Carboplatin & weekly paclitaxel (Taxol) (for anal cancer) Carboplatin and weekly paclitaxel (Taxol) (for anal cancer) The possible benefits of treatment vary; for some people chemotherapy may reduce the
Advance Statements. What is an Advance Statement? Information Line: Website: compassionindying.org.uk
Information Line: 0800 999 2434 Website: compassionindying.org.uk This factsheet explains what an Advance Statement is and how to make one. It is for people living in England and Wales. If you live in
Vinblastine (Lymphoma)
Vinblastine (Lymphoma) Vinblastine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
Capecitabine (Xeloda) tablets
Capecitabine (Xeloda) tablets This is used with radiotherapy to treat colorectal cancer Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy
For the Patient: Fludarabine injection Other names: FLUDARA
For the Patient: Fludarabine injection Other names: FLUDARA Fludarabine (floo-dare-a-been) is a drug that is used to treat many types of cancer. It is a clear liquid that is injected into a vein. Tell
Trastuzumab (Early breast cancer)
Trastuzumab (early breast cancer) Trastuzumab (Early breast cancer) What is Trastuzumab? Trastuzumab is a monoclonal antibody that uses a targeted approach to treat breast cancer. This type of treatment
Oral cyclophosphamide in ovarian cancer
Oral cyclophosphamide in ovarian cancer Oral cyclophosphamide in ovarian cancer This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy